London, United Kingdom · Founded 2020 · Privately Held (backing)
Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. ArkVax is based in London, United Kingdom and was founded in 2020.
Last price · $/share
—
Implied valuation
—
Total raised
—
Last round
—
Cap table — not yet on record
ArkVax's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ArkVax with a free account
·Watch ArkVax: the Monday email on marks, rounds and moves
